Patents by Inventor Yosef Refaeli

Yosef Refaeli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for the cryopreservation of immune cells
    Patent number: 12250943
    Abstract: Provided herein are compositions and methods for the cryopreservation of immune cells, such as peripheral blood mononuclear cells (PBMCs) by pre-treating the cells with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein) prior to freezing. Kits for practicing the methods are also provided herein.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: March 18, 2025
    Assignee: HTYR Acquisition LLC
    Inventors: Yosef Refaeli, Brian C. Turner, Thomas R. Payne
  • MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENIFYING AGENTS THAT MODULATE MYC
    Publication number: 20240156957
    Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Application
    Filed: January 26, 2024
    Publication date: May 16, 2024
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Antibodies and processes for preparing the same
    Patent number: 11667695
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: June 6, 2023
    Assignee: Taiga Biotechnologies, Inc.
    Inventors: Yosef Refaeli, Brian Turner
  • PTD-SMAD7 THERAPEUTICS
    Publication number: 20220370560
    Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.
    Type: Application
    Filed: April 22, 2022
    Publication date: November 24, 2022
    Inventors: Xiao-Jing Wang, Qinghong Zhang, Yosef Refaeli
  • Compositions and methods for modulating immune cells
    Patent number: 11369678
    Abstract: Disclosed herein are methods of modulation of the viability of a cell using fusion proteins comprising a transporter peptide sequence and a MYC polypeptide. Further disclosed herein are methods of modulating an immune response using the fusion proteins. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: June 28, 2022
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Nanoparticle formulations
    Patent number: 11116796
    Abstract: This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: September 14, 2021
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian Curtis Turner, Yosef Refaeli, Gregory Alan Bird
  • Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
    Patent number: 10953048
    Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: March 23, 2021
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory Alan Bird
  • Methods and compositions for the treatment of melanoma
    Patent number: 10864259
    Abstract: Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: December 15, 2020
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian C. Turner, Gregory Alan Bird
  • Production and use of red blood cells
    Patent number: 10786534
    Abstract: The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: September 29, 2020
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory A. Bird
  • Conditionally immortalized long-term stem cells and methods of making and using such cells
    Patent number: 10760055
    Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 1, 2020
    Assignees: NATIONAL JEWISH HEALTH, THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: John C. Cambier, Yosef Refaeli, Sara Ann Johnson, Brian Curtis Turner
  • Nanoparticle formulations
    Patent number: 10583156
    Abstract: This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 10, 2020
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian Curtis Turner, Yosef Refaeli, Gregory Alan Bird
  • Compositions and methods for modulating an immune response
    Patent number: 10556006
    Abstract: Disclosed herein are methods of modulation of the viability of a cell using fusion proteins comprising a transporter peptide sequence and a MYC polypeptide. Further disclosed herein are methods of modulating an immune response using the fusion proteins. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: February 11, 2020
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • PTD-SMAD7 therapeutics
    Patent number: 10456448
    Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: October 29, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Xiao-Jing Wang, Qinghong Zhang, Yosef Refaeli
  • Antibodies and processes for preparing the same
    Patent number: 10442853
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: October 15, 2019
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Turner
  • Therapeutic applications of Smad7
    Patent number: 10350265
    Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 16, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Xiao-jing Wang, Yosef Refaeli, Qinghong Zhang
  • Production and use of red blood cells
    Patent number: 10272115
    Abstract: The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 30, 2019
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory A. Bird
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
    Publication number: 20190060434
    Abstract: Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
    Type: Application
    Filed: November 8, 2018
    Publication date: February 28, 2019
    Inventors: Yosef Refaeli, Brian C. Turner, Gregory Alan Bird
  • Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
    Patent number: 10206952
    Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: February 19, 2019
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory Alan Bird
  • Methods and compositions for the treatment of melanoma
    Patent number: 10149898
    Abstract: Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: December 11, 2018
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian C. Turner, Gregory Alan Bird
  • Expansion of adult stem cells in vitro
    Patent number: 10087420
    Abstract: Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: October 2, 2018
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian Curtis Turner, Yosef Refaeli, Gregory Bird